阻塞性睡眠呼吸暂停治疗对床伴心血管及睡眠健康的影响:睡眠伴侣临床试验
这项安慰剂对照试验将63对中重度OSA患者及其床伴随机分为CPAP组或鼻贴安慰剂组,3个月后评估床伴的内皮功能、血压、睡眠问卷及活动记录。结果显示CPAP未改善床伴内皮功能,但阻止了血压升高,并改善了睡眠质量、日间嗜睡和睡眠碎片化。
要点
- CPAP治疗未显著改善床伴的内皮功能。
- CPAP组床伴24小时及日间收缩压较安慰剂组降低。
- CPAP组床伴睡眠质量、日间嗜睡及睡眠碎片化均改善。
核心结论
- OSA治疗未改善床伴内皮功能,但阻止了血压升高,并改善了睡眠质量、日间嗜睡和睡眠碎片化。
研究设计与样本
- 安慰剂对照试验,共纳入63对中重度OSA患者及其床伴,患者随机接受CPAP(34例)或鼻贴安慰剂(29例),床伴在基线和3个月后接受临床评估、内皮功能(FMD)、24小时动态血压监测、睡眠问卷和1周腕部活动记录。
主要发现
- 床伴基线时FMD受损,且长睡眠潜伏期、睡眠碎片化、短睡眠时长和睡眠质量差的发生频率较高。
- CPAP组与安慰剂组床伴FMD变化无显著差异(Δ: -0.94% (6.03%; 2.24%) vs Δ: -3.27% (-6.50%; 1.76%),p=0.67)。
- CPAP组床伴24小时收缩压变化为-0.85±5.22 mm Hg,安慰剂组为+3.14±8.00 mm Hg(p=0.03)。
- CPAP组床伴日间收缩压变化为-1.2±5.5 mm Hg,安慰剂组为+3.8±8.8 mm Hg(p=0.01);夜间心率变化为-3±6 bpm vs +2±7 bpm(p=0.01)。
- CPAP组床伴睡眠质量改善(p=0.02)、日间嗜睡减少(p=0.01)、入睡后觉醒时间减少(CPAP: -4.71±20.32 min; 安慰剂: +7.36±17.51 min; p=0.002)及觉醒次数减少(CPAP: -0.97±9.42; 安慰剂: +2.83±9.14; p=0.02)。
临床怎么用
- 对中重度OSA患者进行CPAP治疗可能通过阻止床伴血压升高和改善睡眠质量带来间接获益。
- 评估OSA治疗对床伴的影响时,需关注CPAP依从性,≥6小时/晚可能对床伴内皮功能有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains unclear whether obstructive sleep apnoea (OSA) and its treatment influence cardiovascular and sleep health in bed partners. METHODS: In this placebo-controlled trial, patients with moderate/severe OSA who had bed partners were randomly assigned to receive continuous positive airway pressure (CPAP) or placebo (nasal strips). At baseline and after 3 months, the bed partners underwent clinical evaluation, endothelial function (flow-mediated dilation, FMD), 24-hour ambulatory blood pressure (BP) monitoring, sleep questionnaires and 1-week wrist actigraphy. RESULTS: A total of 63 couples were recruited (34 patients randomised to CPAP and 29 to nasal strips). At baseline, bed partners showed impaired FMD and a higher frequency of long sleep latency, fragmented sleep, short sleep duration and poor sleep quality. Mean adherence to CPAP and nasal strips in OSA patients was 5.7±1.7 hours and 93.1%±12.6%, respectively. Compared with placebo, bed partners of patients assigned to CPAP did not change FMD (Δ: -0.94% (6.03%; 2.24%) vs Δ: -3.27% (-6.50%; 1.76%), p=0.67). However, significant differences were observed for 24-hour systolic BP (CPAP: -0.85±5.22 mm Hg; placebo: +3.14±8.00 mm Hg; p=0.03), daytime systolic BP (CPAP: -1.2±5.5 mm Hg; placebo: +3.8±8.8 mm Hg; p=0.01) and night-time heart rate (CPAP: -3±6 bpm; placebo: +2±7 bpm; p=0.01). They improved sleep quality (p=0.02), decreased daytime sleepiness (p=0.01), time awake after sleep onset (CPAP: -4.71±20.32 min; placebo: +7.36±17.51 min; p=0.002) and number of awakenings (CPAP: -0.97±9.42; placebo: +2.83±9.14; p=0.02). In a stratified analysis by CPAP adherence, endothelial function in bed partners was preserved with optimal use (≥6 hours/night), but worsened with lower adherence (p=0.03). CONCLUSIONS: OSA treatment did not improve endothelial function in bed partners but prevented BP increases, alongside improvements in sleep quality, daytime sleepiness and sleep fragmentation. TRIAL REGISTRATION NUMBER: NCT03011294.
引用
- Giampá SQC, Furlan SF, Macedo TA, et al. Effects of obstructive sleep apnoea treatment on cardiovascular and sleep health in bed partners: the sleep partners clinical trial. Thorax. 2026. PMID: 42772900. doi:10.1136/thorax-2026-225271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。